Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this prospective study, 68Ga-PSMA integrated PET/MR imaging was applied for the diagnosis and staging of hepatocellular carcinoma (HCC). The detection and diagnostic performance of 68Ga-PSMA PET/MR for HCC was evaluated in comparison with the gold standard of puncture biopsy or postoperative pathology. The aim is to make up for the deficiency in FDG PET imaging in the diagnosis and staging of HCC.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan Union Hospital, China
• Treatments: Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

Each subject must meet all the inclusion criteria to be eligible for the study.

• Subjects or their legal representatives are able to sign an informed consent form

• Subjects are committed to comply with the study procedures and cooperate with the implementation of the full study

• Subjects are 18 years of age or older, regardless of gender

• Subjects with high suspicion of HCC, or diagnosed HCC without tumour-related treatment (supporting evidence including serum AFP, MRI, CT and other imaging data and histopathology), and in good general condition

• Subjects intend to obtain pathological results by biopsy or surgical resection

Exclusion Criteria:

All patients meeting any of the exclusion criteria will be excluded from the study.

• Patients or their legal representatives are unable or unwilling to sign the informed consent form

• Patients are unable to cooperate in the conduct of the full study

• Patients with acute systemic illness and electrolyte disturbances

• Patients with other previous malignancies or a combination of other malignancies

• Patients who are pregnant or lactating women